So, we have an alternative to Tobi that for a small number of patients may have slightly more coughing and sore throat issues. It is a once per day dosing that will dramatically improve compliance and, of course, lower hospitalization related issues and costs. As Tobi becomes ineffective over time it will supplement or even become the primary product over time for many patients. And, it may well not be subject to the longer tem downtrend in effectiveness that Tobi sees. Maybe not a home run but a double or triple.
Yep, Tobi was trending down in improvements in lung function (the expected stairstep down) while Arikace was trending sideways with no loss in efficacy. Would have been interesting to see this trial continued over a few more cycles.